PSD Bank Rhein-Ruhr eG

Suchergebnis - SHANGHAI JUNSHI BIOSC. CO.LTD. REGISTERED SHARES H YC 1 YC1

Zeit	Titel
25.04 04:11	dpa-AFX: GNW-Adhoc: Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
29.03 05:24	dpa-AFX: GNW-Adhoc: Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
02.02 04:40	dpa-AFX: GNW-Adhoc: Junshi Biosciences Announces Toripalimab's NDA Accepted by the Singapore Health Sciences Authority
18.01 05:05	dpa-AFX: GNW-Adhoc: Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer
10.01 04:15	dpa-AFX: GNW-Adhoc: Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine
02.01 14:00	dpa-AFX: GNW-Adhoc: Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients
02.12 04:39	dpa-AFX: GNW-Adhoc: Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia's TGA
23.11 02:08	dpa-AFX: GNW-Adhoc: Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19
27.10 18:16	dpa-AFX: GNW-Adhoc: Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023
31.08 05:34	dpa-AFX: GNW-Adhoc: Junshi Biosciences Announces 2023 Interim Financial Results and Provides Corporate Updates
20.07 04:49	dpa-AFX: GNW-Adhoc: Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer
12.07 03:17	dpa-AFX: GNW-Adhoc: Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab
29.06 07:59	dpa-AFX: GNW-Adhoc: Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer